Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

被引：12

作者：

Gilabert, Marine ^{[1
,2
]}

Raoul, Jean-Luc ^{[3
]}

机构：

[1] Paoli Calmettes Inst, Dept Med Oncol, 232 Bd St Marguerite, F-13232 Marseille 9, France

[2] Aix Marseille Univ, Inst Natl Sante & Rech Med 1068, Stress Cell Unit, Ctr Rech Cancerol Marseille, Marseille 8, France

[3] Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, F-44805 Nantes, France

来源：

JOURNAL OF HEPATOCELLULAR CARCINOMA | 2018年 / 5卷

关键词：

hepatocellular carcinoma; antiangiogenic drugs; ramucirumab; RANDOMIZED PHASE-III; DOUBLE-BLIND; 1ST-LINE TREATMENT; OPEN-LABEL; SORAFENIB; PLACEBO; CHEMOTHERAPY; MULTICENTER; COMBINATION; THERAPY;

D O I：

10.2147/JHC.S157413

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) represents similar to 90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first-and second-line treatment. This study focused on the efficacy of antiangiogenics in patients with advanced HCC and particularly the rising role of ramucirumab in patients with elevated alpha-fetoprotein at diagnosis.

引用

页码：91 / 98

页数：8

共 54 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2]

[Anonymous], JAMA ONCOL

[3]

[Anonymous], 2018 ASCO ANN M JUN

[4]

[Anonymous], 2018, Journal of Hepatology

[5]

[Anonymous], J CLIN ONCOL S

[6]

[Anonymous], 2018 ASCO ANN M JUN

[7]

[Anonymous], J CLIN ONCOL

[8] NCCN Guidelines® Insights Hepatobiliary Cancers, Version 1.2017 Featured Updates to the NCCN Guidelines [J].

Benson, Al B., III ;

D'Angelica, Michael I. ;

Abbott, Daniel E. ;

Abrams, Thomas A. ;

Alberts, Steven R. ;

Saenz, Daniel Anaya ;

Are, Chandrakanth ;

Brown, Daniel B. ;

Chang, Daniel T. ;

Covey, Anne M. ;

Hawkins, William ;

Iyer, Renuka ;

Jacob, Rojymon ;

Karachristos, Andrea ;

Kelley, R. Kate ;

Kim, Robin ;

Palta, Manisha ;

Park, James O. ;

Sahai, Vaibhav ;

Schefter, Tracey ;

Schmidt, Carl ;

Sicklick, Jason K. ;

Singh, Gagandeep ;

Sohal, Davendra ;

Stein, Stacey ;

Tian, G. Gary ;

Vauthey, Jean-Nicolas ;

Venook, Alan P. ;

Zhu, Andrew X. ;

Hoffmann, Karin G. ;

Darlow, Susan .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (05) :563-573

[9] Prognostic prediction and treatment strategy in hepatocellular carcinoma [J].

Bruix, J ;

Llovet, JM .

HEPATOLOGY, 2002, 35 (03) :519-524

[10] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

← 1 2 3 4 5 6 →